CTTQ
Status and phase
Conditions
Treatments
About
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
528 participants in 2 patient groups
Loading...
Central trial contact
Ruihua Xu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal